Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Chemomab Therapeutics Ltd. CMMB
$1.53
-$0.08 (-5.26%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
17679680.00000000
-
week52high
5.35
-
week52low
1.38
-
Revenue
0
-
P/E TTM
-1
-
Beta
-0.23409300
-
EPS
-2.35000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 10:59
Описание компании
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 10 мар 2022 г. |
| Aegis Capital | Buy | 07 дек 2021 г. | |
| Cantor Fitzgerald | Overweight | 26 мая 2021 г. | |
| Oppenheimer | Outperform | 07 мая 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| OrbiMed Israel GP Ltd. | D | 2241274 | 70524 | 03 янв 2023 г. |
| OrbiMed Israel GP Ltd. | D | 2311798 | 266376 | 03 янв 2023 г. |
| Mor George Adi | D | 251147 | 6100 | 03 янв 2023 г. |
| Mor George Adi | D | 317075 | 7700 | 03 янв 2023 г. |
| Cohen Neil Harris | D | 10000 | 2409 | 16 ноя 2022 г. |
| Mor George Adi | D | 257247 | 257248 | 16 ноя 2022 г. |
| Mor George Adi | D | 324775 | 324775 | 16 ноя 2022 г. |
| Maryles Joel Michael | A | 11884 | 11884 | 24 мая 2022 г. |
| Maryles Joel Michael | A | 6820 | 6820 | 24 мая 2022 г. |
| Maryles Joel Michael | A | 1433 | 33 | 24 мая 2022 г. |
Новостная лента
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
PRNewsWire
06 мар 2023 г. в 07:00
TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023.
Chemomab (CMMB) Stock Gains 30% on FDA Clearance
InvestorPlace
21 февр 2023 г. в 11:43
There's potentially positive news for the medical community as well as investors of Chemomab (NASDAQ: CMMB ) today. CMMB stock is moving higher because Chemomab has good news on the regulatory front, plus the company expects to move forward with important clinical research.
Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment
Market Watch
21 февр 2023 г. в 08:25
Shares of Chemomab Therapeutics Ltd. CMMB, -0.51% shot up 46.9% in premarket trading Tuesday, after the Israel-based biotechnology company said the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application to evaluate its systemic sclerosis (SSc) treatment, CM-101.
Chemomab Therapeutics Ltd. (CMMB) Q3 2022 Earnings Call Transcript
Seeking Alpha
11 ноя 2022 г. в 12:00
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Don Marvin - Chief Financial Officer, Executive Vice President and Chief Operating Officer Adi Mor - Co-Founder and Chief Scientific Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab's Third Quarter 2022 Earnings Conference Call.
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
PRNewsWire
28 окт 2022 г. в 07:00
TEL AVIV, Israel , Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November.